Citations

Clear

16280 citation(s) found for "Yu, David".

TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications
Chatterjee, Rishita , Selvadurai, Boobash Raj , Verma, Aakanksha , Giri, Suvendu , Genna, Alessandro , Karatekin, Feride , Zerbib, Mirie , Vinik, Yaron , Avioz, Tamir, Weizman, Eviatar , Pan, Yunqian , Hunt, Hazel , Ku, Anson T. , Kartal, Sumeyra, Bright, Jack R., Dahut, William L. , Sowalsky, Adam G. , Yarden, Yosef, Sowalsky, Adam G , Sekar, Arunachalam , Pal, Lipika R. , Nataraj, Nishanth Belugali , Garcia, Diana Drago , Gupta, Nitin, Weizman, Eviatar , David, Eyal , Schäffer, Alejandro A. , Huang, Haojie , Weerden, Wytske M. van , Corey, Eva , Greenstein, Andrew E. , Blecher‐Gonen, Ronnie , Oren, Roni , Afek, Ariel , Amit, Ido , Lev, Sima , Kartal, Sumeyra , Bright, Jack R., Lis, Rosina T. , Ruppin, Eytan

Mayo Clinic

No container title available | January 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.17.633582 | PMID 40568162 Get It

Abstract Approximately 50% of prostate cancer (PCa) patients harbor fusions involving the TMPRSS2 and ERG genes. Despite this, tailored therapies targeting the fused gene, tERG , remain undeveloped. Our study analyzed biopsy samples from two clinical trials assessing the efficacies of androgen receptor (AR) signaling inhibitors (ARSIs). The results revealed that tERG promotes resistance to ARSIs and is associated with elevated levels of the glucocorticoid receptor (GR). Subsequent assays showed that GR directly interacts with tERG, alleviates allosteric autoinhibition and prevents chemotherapy-induced tERG degradation. In PCa models, either inhibiting GR or lowering cortisol levels suppressed tumor growth in tERG-positive models, but not in fusion-negative models. In addition, patient-derived fusion-positive xenografts displayed enhanced sensitivity to combined GR and AR inhibitors. Collectively, these findings highlight TMPRSS2-ERG as a new biomarker and propose that simultaneous inhibition of GR and AR may specifically benefit tERG -positine patients. However, GR stimulatory corticosteroid therapies may not be advisable for this patient subgroup.
The Association Between Myasthenia Gravis and Higher Extrathymic Cancer Risk
Khateb, Mohamed , Zant, Mai Abu, Bsoul, Alaa, Karny, Tomer, Shelly, Shahar, Karny, Tomer, Yarnitsky, David , Shelly, Shahar

Mayo Clinic

Brain and Behavior | January 20, 2025 | Volume: 15 | Issue: 1 | Pages: No page available

10.1002/brb3.70143 | PMID 39829143 Get It

ABSTRACT Background Myasthenia gravis (MG) is strongly associated with thymic tumors, but whether it is also associated with extrathymic cancers is debatable or whether MG can be considered a paraneoplastic disorder for extrathymic cancers. Methods This is a retrospective analysis of the MG cohort for 23 years' time (January 2000 to May 2023), extracting cancer rates with clinical, electrophysiological, and biochemical cancer associations and the effect of chronic medications. Results We identified 436 patients with MG and 3924 controls. The median age at symptom onset was 64 (5–93 years) for males and 54 (1–87 years) for females. MG symptoms at onset were recorded as ocular (60%), strictly bulbar (10%), or generalized (23%). Extrathymic cancer was found in 32% of MG patients. In 3%, thymic and extrathymic cancers co‐occurred. Compared to controls, neurology (12.2%, 159/1308), internal medicine (24.4%, 319/1308), or rheumatology (12%, 157/1308), MG patients had significantly higher rates of extrathymic cancers ( p < 0.001). Compared to the rheumatology group, the cancer relative risk of 2.97, CI = 2.5–3.4. Furthermore, the prevalence of extrathymic cancers was significantly increased within the paraneoplastic time window, defined as ±5 years from cancer diagnosis to myasthenia onset ( p < 0.01). Conclusion MG was significantly associated with an increased risk of extrathymic cancers, particularly within the paraneoplastic time window. These findings suggest that MG might potentially behave as a paraneoplastic disorder.
Immunotherapy‐Resistant Neuropathic Pain and Fatigue Predict Quality‐of‐Life in Contactin‐Associated Protein‐Like 2 Antibody Disease
Ceronie, Bryan , Strippel, Christine , Uy, Christopher , Paneva, Sofija , Makuch, Mateusz , Soleimani, Babak , Turaga, Sanchit, Ramanathan, Sudarshini , Michael, Sophia , Varley, James , Easton, Ava , Bennett, David , Irani, Anushka , Irani, Sarosh R. , Ramanathan, Sudarshini , Themistocleous, Andreas , Bennett, David L , Irani, Anushka , Irani, Sarosh R , Paneva, Sofija , Binks, Sophie , Dawes, John M. , Handel, Adam E.

Mayo Clinic

Annals of Neurology | January 18, 2025 | Volume: 97 | Issue: 3 | Pages: 521-528

10.1002/ana.27177 | PMID 39825737 Get It

The long‐term clinical outcomes and associated prognostic factors in contactin‐associated protein‐like 2 (CASPR2)‐antibody diseases are unknown. A total of 75 participants with CASPR2 antibodies were longitudinally assessed for disability, quality‐of‐life, and chronic pain. Although most symptoms improved within 6 months of treatment, neuropathic pain and fatigue were the most immunotherapy refractory, and persisted for up to 6 years. Furthermore, these two factors—but not CASPR2 antibody levels or subclasses—independently predicted worse disability and quality‐of‐life at 24 months. Quality‐of‐life varied widely for any given modified Rankin Scale score, indicating a divergence between patient and clinician assessed outcomes. Further work should study the relative importance of these measures, and the immunopathogenesis underlying intractable symptoms. ANN NEUROL 2025;97:521–528
Outcomes of Coccidioides Seropositive Solid Organ Transplant Recipients After Self-discontinuation of Antifungal Prophylaxis: The EIA-IgM-only Conundrum
Biondi, Matt V., Shah, P. , Kodali, Lavanya , Chascsa, David M. , Blair, Janis E. , Biondi, Matt , Gupta, Simran , Shah, Priyal J , Chascsa, David M H, Buras, Matthew , Vikram, Holenarasipur R. , Biondi, Matt

Mayo Clinic

Transplantation | January 17, 2025 | Volume: 109 | Issue: 7 | Pages: 1251-1256

10.1097/tp.0000000000005304 | PMID 39821091 Get It

Background. Solid organ transplant recipients are at risk of severe coccidioidomycosis and are given prophylaxis to mitigate the risk. Patients with seropositive testing typically receive lifelong prophylaxis; currently, this prophylaxis strategy includes patients who are positive only for IgM by enzyme immunoassay (EIA-IgM-only), although this result may be falsely positive. Methods. We conducted a retrospective study at a large-volume transplant center in an endemic coccidioidomycosis region to compare outcomes of non–lung transplant recipients who were seropositive for Coccidioides but discontinued prophylaxis (case patients) to outcomes of patients who continued prophylaxis (controls). Results. No case or control patients developed active coccidioidomycosis during the follow-up period. Before transplant, 62 of 77 case patients (80.5%) had a single positive serologic test, of whom 27 of 62 were EIA-IgM-only positive (43.5%). In contrast, 57 of 77 controls (74.0%) had a single seropositive result (16/57 [28.1%] were EIA-IgM-only). The single EIA-IgM-only result was classified as falsely positive by infectious disease consultants in 20 of 43 patients (46.5%) compared with all other Coccidioides serologic results (13/111 [11.7%], P < 0.001). Lifetime antifungal prophylaxis was felt to be unnecessary for 28 of 43 patients (65.1%) who were EIA-IgM-only versus 31 of 111 patients (27.9%) with other serologic results (P < 0.001). Conclusions. For patients repeatedly positive for EIA-IgM-only and no evidence of seroconversion, compatible clinical illness, or radiographic findings, discontinuing antifungal prophylaxis may be reasonable after the first posttransplant year.
The effects of admission hyperglycemia and diabetes mellitus on mechanical thrombectomy outcomes: A systematic review and meta-analysis
Bilgin, Gokce Belge , Bilgin, Cem , Jabal, Mohamed Sobhi , Kobeissi, Hassan , Ghozy, Sherief , Şenol, Yiğit Can , Orscelik, Atakan , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Belge Bilgin, Gokce , Ghozy, Sherief , Kobeissi, Hassan , Orscelik, Atakan , Senol, Yigit Can , Bilgin, Cem , Rabinstein, Alejandro A.

Mayo Clinic

Interventional Neuroradiology | January 17, 2025 | Volume: 32 | Issue: 4 | Pages: 1831-1842

10.1177/15910199241306774 | PMID 39819212 Get It

Background The impact of certain comorbidities on mechanical thrombectomy (MT) outcomes remains largely unexplored. Diabetes mellitus (DM) and admission hyperglycemia have been associated with poor clinical outcomes for patients treated with MT. In this study, we sought to investigate the effects of DM and admission hyperglycemia on MT outcomes. Methods Following PRISMA guidelines, a systematic literature search was conducted in Medline, Embase, Scopus, and Web of Science databases. Data regarding successful recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] ≥2b), functional independence (modified Rankin Scale [mRS] 0–2), excellent outcomes (mRS 0–1), symptomatic intracranial hemorrhage (sICH), and mortality were extracted from the included studies. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated using random effects model. Results Twenty-one studies comprising 9708 patients were included. A total of 2311 patients (24%) had a history of DM, and 2026 patients (21%) had admission hyperglycemia. Admission hyperglycemia was associated with significantly lower odds of mTICI ≥2b (OR = 0.7, 95% CI = 0.55–0.89), mRS 0–2 (OR = 0.47, 95% CI = 0.41–0.53), and mRS 0–1 (OR = 0.43, 95% CI = 0.34–0.55) as compared to normoglycemic state. Patients with hyperglycemia had significantly higher rates of sICH (OR = 2.05, 95% CI = 1.66–2.54) and mortality (OR = 1.99, 95% CI = 1.58–2.52) than normoglycemic patients. Diabetes mellitus was associated with significantly high rates of mortality (OR = 1.74, 95% CI = 1.31–2.3) and lower rates of mRS 0–2 (OR = 0.60, 95% CI = 0.48–0.76) in sensitivity analyses. Conclusion Our results indicate that admission blood glucose levels and DM can negatively affect MT outcomes. Further research should focus on optimizing MT outcomes for these patients.
INSIDE-OUT: Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over Time
Marcelin, Jasmine R , Lyden, Elizabeth , Abdul‐Mutakabbir, Jacinda C. , Kullar, Ravina , Ristagno, Elizabeth H. , Time), the INSIDE-OUT Study Group (Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over, Rajapakse, Nipunie , Patel, Megha, Miller, Amy M. , Oeltjen, Erin N, Semaj, Sophie, Sramek, Kyle T, Lindeman, Christopher J, Daubach, Eric C., Akinmoladun, Oladapo O, Wurtz, Paul J, Ristagno, Elizabeth H , Marcelin, Jasmine , Khazanchi, Rohan , Cawcutt, Kelly , Ha, David R , Florez, Narjust , Time), the INSIDE-OUT Study Group (Introduction of Speakers at IDWeek Events—Observing for Unconscious Bias Over, Patel, Megha, Akinmoladun, Oladapo O., Yang, Yuhong

Mayo Clinic

Open Forum Infectious Diseases | January 17, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1093/ofid/ofaf024 | PMID 39963695 Get It

Abstract Background Specialty societies, including the Infectious Diseases Society of America, strive to address gender and racial inequities in professional advancement. Microaggressions remain a persistent and pervasive barrier to these goals. Nonprofessional speaker introductions are a manifestation of race- and gender-based microaggressions, which have not been previously assessed at IDWeek. We assessed disparities in speaker introductions at IDWeek over a 7-year period that included formal gender equity initiatives introduced in 2016. Methods We conducted a retrospective observational study of video-recorded IDWeek speaker introductions from 2013 to 2019. Trained coders reviewed presentation video archives to assess a primary outcome of nonprofessional introductions: when a speaker's professional title was not used as the first introduction. We used descriptive statistics, Fisher exact tests, Cochrane-Armitage trend tests, and multivariable logistic regression to characterize relationships between speaker introductions and presentation year, speaker demographics, and speaker-moderator demographic concordance. Results Of 1940 videos reviewed, 48.9% of IDWeek speakers received nonprofessional introductions during and before 2016 vs 41.5% of speakers after 2016 (P = .0013). There was an increasing linear trend in the frequency of professional introductions by speaker age group from 47.1% for age &lt;40 years to 65.3% for age &gt;60 years (P &lt; .0001). White moderators more frequently used nonprofessional introductions than moderators from backgrounds underrepresented in medicine (47.7% vs 29.1%, P = .0014). Women-men speaker-moderator pairs had more nonprofessional introductions (54.6%, P &lt; .001). Conclusions In the largest assessment of microaggressions in speaker introductions at a national medical specialty conference, we highlighted some progress over time and ample opportunity to further standardize equitable speaker introductions, especially for women and junior speakers
Characterization of Human Senescent Cell Biomarkers for Clinical Trials
Monroe, David G. , Atkinson, Elizabeth J. , Froemming, Mitchell N. , Ruan, Ming, LeBrasseur, Nathan K. , Khosla, Sundeep , Monroe, David G , LeBrasseur, Nathan K , Khosla, Sundeep , Farr, Joshua N.

Mayo Clinic

Aging Cell | January 17, 2025 | Volume: 24 | Issue: 5 | Pages: No page available

10.1111/acel.14489 | PMID 39823170 Get It

ABSTRACT There is an increasing need for biomarkers of senescent cell burden to facilitate the selection of participants for clinical trials. p16 Ink4a is encoded by the CDKN2A locus, which produces five variant transcripts in humans, two of which encode homologous p16 proteins: p16 Inka4a , encoded by p16_variant 1 , and p16ɣ, encoded by p16_variant 5. While distinct quantitative polymerase chain reaction primers can be designed for p16_variant 5, primers for p16_variant 1 also measure p16_variant 5 ( p16_variant 1 + 5 ). In a recent clinical trial evaluating the effects of the senolytic combination, dasatinib + quercetin (D + Q), on bone metabolism in postmenopausal women, we found that women in the highest tertile for T‐cell expression of p16_variant 5 had the most robust skeletal responses to D + Q. Importantly, the assessment of p16_variant 5 was more predictive of these responses than p16_variant 1 + 5 . Here, we demonstrate that in vitro, p16_variant 1 + 5 increased rapidly (Week 1) following the induction of DNA damage, whereas p16_variant 5 increased later (Week 4), suggesting that p16_variant 5 becomes detectable only when the abundance of senescent cells reaches some threshold. Further analysis identified a SASP panel in plasma that performed as well in identifying postmenopausal women with a positive skeletal response to D + Q. Collectively, our findings provide further support for the T‐cell p16_variant 5 assay as a biomarker for selecting participants in clinical trials of senolytic interventions. In addition, our data indicate that correlated plasma SASP markers could be used in lieu of the more technically challenging T‐cell p16 assay. Trial Registration: ClinicalTrials.gov identifier: NCT04313634.
Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis
Gupta, Vinod K. , Janda, Guneet, Pump, Heather K. , Lele, Nikhil , Cruz, Isabella, Cohen, Inessa , Hafler, David A. , Sung, Jaeyun , Longbrake, Erin E. , Hafler, David A , Longbrake, Erin E , Pump, Heather , Sung, Jaeyun , Ruff, William E.

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | January 16, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1212/nxi.0000000000200355 | PMID 39819054 Get It

Artificial intelligence models using F-wave responses predict amyotrophic lateral sclerosis
Martinez‐Thompson, Jennifer M. , Cantu, Carolina Parra, Naddaf, Elie , Gogineni, Venkatsampath, Botha, Hugo , Jones, David T. , Laughlin, Ruple S. , Barnard, Leland R , Staff, Nathan P. , Mazurek, Kevin A , Naddaf, Elie , Botha, Hugo , Jones, David T , Staff, Nathan P , Mazurek, Kevin A.

Mayo Clinic

Brain | January 16, 2025 | Volume: 148 | Issue: 7 | Pages: 2320-2330

10.1093/brain/awaf014 | PMID 39820267 Get It

Abstract Nerve conduction F-wave studies contain crucial information about subclinical motor dysfunction that can be used to diagnose patients with amyotrophic lateral sclerosis (ALS). However, F-wave responses are highly variable in morphology, making waveform interpretation challenging. Artificial intelligence techniques can extract time–frequency features to provide new insights into ALS diagnosis and prognosis. A retrospective analysis was performed on F-wave responses from 46 802 patients. Discrete wavelet transforms were applied to time-series waveform responses after stimulating ulnar, median, fibular and tibial nerves. Wavelet coefficient statistics, onset age, sex and body mass index were features for training a Gradient Boosting Machine model on 40 095 patients (5329 diagnosed with motor neuron disease). Model performance was tested on responses from 689 ALS patients meeting Gold Coast criteria and 689 age- and sex-matched controls. An exploratory analysis examined model performance on cohorts of patients with inclusion body myositis, cervical radiculopathy, lumbar radiculopathy or peripheral neuropathy, which can mimic ALS symptoms. Factors affecting survival were estimated through Cox proportional hazards regression. The model trained using wavelet features on the full waveform had 90% recall, 87% precision and 88% accuracy. Similar model performance was measured using features from only the M-wave or F-wave. Classification probabilities for ALS patients were statistically different from the diagnoses mimicking ALS symptoms (P &lt; 0.001, ANOVA, Tukey’s post hoc test). Higher model classification probabilities of ALS, older age at onset, and family history of ALS alone or with frontotemporal dementia were factors decreasing survival. Longer diagnostic delay and upper limb onset site were factors increasing survival. Model scores two standard deviations below the mean had 4 months increased survival (two standard deviations below had 3 months decreased survival). Artificial intelligence techniques extracted important information from F-wave responses to estimate a patient’s likelihood of ALS and their survival risks. Although the model can make predictions at a specific decision threshold as presented here, the true strength of such a model lies in its ability to provide probabilities about whether a patient is likely to have ALS in comparison to other mimicking diagnoses, such as inclusion body myositis, cervical or lumbar radiculopathy or peripheral neuropathy. These probabilities provide clinicians with additional information that they can use to make the final diagnosis with greater confidence and precision. Integrating such a model into the clinical workflow could help clinicians to diagnose ALS sooner and manage treatment based on estimated survival, which might improve outcomes and the quality of life of patients.